Bobby Gaspar
2021
In 2021, Bobby Gaspar earned a total compensation of $4.4M as Chief Executive Officer at Orchard Therapeutics plc, a 15% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $217,841 |
|---|---|
| Option Awards | $3,504,354 |
| Salary | $605,114 |
| Other | $27,230 |
| Total | $4,354,539 |
Gaspar received $3.5M in option awards, accounting for 80% of the total pay in 2021.
Gaspar also received $217.8K in non-equity incentive plan, $605.1K in salary and $27.2K in other compensation.
Rankings
In 2021, Bobby Gaspar's compensation ranked 3,046th out of 12,415 executives tracked by ExecPay. In other words, Gaspar earned more than 75.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,046 out of 12,415 | 76th |
Division Manufacturing | 1,216 out of 5,508 | 78th |
Major group Chemicals And Allied Products | 487 out of 2,378 | 80th |
Industry group Drugs | 430 out of 2,099 | 80th |
Industry Biological Products, Except Diagnostic Substances | 121 out of 449 | 73rd |
Source: SEC filing on April 27, 2022.
Gaspar's colleagues
We found one more compensation record of an executive who worked with Bobby Gaspar at Orchard Therapeutics plc in 2021.
2021
Frank Thomas
Orchard Therapeutics plc